Background. The increasing incidence of estrogen-dependent breast cancer and the presence in the environment of a large number of factors that interact with estrogen receptors have sparked interest in chemical influences on estrogen-dependent processes. In a previous work, the authors examined the interaction of estradiol with chromium. In the present article the importance of estradiol biotransformation in these interactions is investigated. There is no information in the available literature about the role of metabolites in exposure to chromium. It seems important because estradiol metabolites have various carcinogenic abilities and their formation during biotransformation could be increased or decreased by environmental enzyme inducers or inhibitors. The metabolites could play a detoxifying role or create a toxic synergism in free radical processes induced by chromium VI (CrVI).
The increasing incidence of estrogen-dependent breast cancer has sparked researchers' interest in the influence of environmental factors on estrogen-dependent processes. The interaction of xenobiotics with estrogens has been widely studied in case of environmental toxins that interact with estrogen receptors (xenoestrogens). However, chromium is recognized as a metalloestrogen, and there are only a few reports in the available literature on chromium/estrogen interaction. [1] [2] [3] There is no information about the role of estradiol metabolites in exposure to chromium. The problem seems important because the metabolites have various carcinogenic abilities, and their formation during estradiol biotransformation could be increased or decreased by environmental enzyme inducers or inhibitors. The main biotransformation pathway of estradiol is hydroxylation. The final products of C-4, C-16 or C-2 hydroxylation are 4-hydroxyestradiol (4-OHE 2 ), 16-α-hydroxyestrone (16α-OHE 1 ) or 2-metoxyestradiol (2-MeOE 2 ) respectively. The role of these metabolites in carcinogenesis is unknown; however, there are some reports on the presence of 4-OHE 2 -adducts in breast cancer tissue and on the anticancer activity of 2-MeOE 2 . 4 Chromium is widely present in the environment. Its toxicity depends on the valence. The International Agency for Research on Cancer (IARC) classifies chromium (VI) as a proven human carcinogen.Interactions between estrogens and carcinogenic factors need special attention because estrogen itself possesses carcinogenic activity, so synergistic effects with carcinogenic chromium could be very dangerous. Because exposure to metals is widespread, an elucidation of their roles in the etiology and development of hormone-related diseases such as breast cancer may have significant implications in risk reduction and disease prevention. Chromium compounds are able to generate free radicals, which have an indisputable role in carcinogenesis. 5 Estrogens in general act as free-radical scavengers, but also demonstrate prooxidative activity. Not only chromium but also estrogens are present in environment. The metabolites of estrogen used in contraception or hormonal replacement therapy are found in ground water and wastewater. They also circulate in the environment via communal waste, increasing the risk of hormonally active compounds interacting with xenobiotics. A number of publications describe the presence of active hormonal compounds originating from waste or breeding farms and their influence on the environment. 6, 7 The authors' previous work demonstrated the protective role of 17β-estradiol (E 2 ) in chromium-induced lipid peroxidation in human erythrocytes, but in the mitochondrial membranes of human placenta, the opposite phenomenon was observed: 17β-estradiol increased CrVI-induced lipid peroxidation in mitochondria, so a toxic interaction was noted. 3 The mechanism of this interaction partially correlated with hydroxyl radical (•OH) formation, since E 2 increased •OH generation in mitochondria exposed to low (0.05 and 0.5 µg/mL) CrVI concentrations. These interactions were not observed for superoxide dismutase (SOD) activity.
It seems valid to assess the role of estradiol metabolites in the processes outlined above. Environmental toxins often change the biotransformation pathways, acting as inductors or inhibitors of particular enzymes. The aim of the present study was to evaluate the influence of estradiol metabolites 4-OHE 2 and 16α-OHE 1 on mitochondria and erythrocytes when exposed to CrVI. There are no data on that topic at present. It is known that the biotransformation of estradiol plays important role in carcinogenesis, and the level of some metabolites, e.g. 16α-OHE 1 ,is increased in women with breast cancer. 8 In this work the influence of 16α-OHE 1 and 4-OHE 2 on the lipid peroxidation level (TBARS) and hydroxyl radical generation (•OH level), elements of the enzymatic and non-enzymatic antioxidant barrier such as superoxide dismutase (SOD), and detoxifying capacity measured by GST activity was tested. All the experiments were conducted on human cells in vitro: erythrocytes of blood or mitochondria obtained from placenta.
Material and methods
The study was conducted on an in vitro model, using human cell erythrocytes and mitochondria. The study was approved by the Wroclaw Medical University Ethics Committee (permit KB-292/2013). Mitochondria were isolated from human placenta, obtained after natural deliveries from the Clinic of Reproduction and Obstetrics, Wroclaw Medical University (Poland), by a previously described method. 9 The isolated mitochondrial pellet was suspended in 50 mMTris-HCl buffer (pH 7.4), and the level of protein was measured usingthe Lowry method. 10 The suspension was portioned into Eppendorf tubes (1 mL) and stored at -80°C, no longer than 3 months before use. The mitochondrial suspension was used for the evaluation of lipid peroxidation (TBARS), hydroxyl radical generation (•OH), superoxide dismutase (SOD) and glutathione-S-transferase (GST) activities.
Fresh human blood taken on sodium citrate for SOD, GST and TBARS determination was obtained from healthy donors at Wroclaw University Hospital. The erythrocytes were isolated by whole blood centrifugation for 10 min at room temperature (3000 rpm). The plasma and white blood cells were then removed and the resulting pellet of erythrocytes was washed 3 times in phosphate buffered saline (PBS). The erythrocytes were suspended in PBS at a 10% concentration for the SOD, GST and TBARS measurements.
Potassium dichromate (K 2 Cr 2 O 7 ) (POCH S.A., Gliwice, Poland) was used as the CrVI source. The CrVI concentrations used in the experiments were 0.05 μg/mL, 0.5 μg/mL and 1.0 μg/mL.
Estradiol metabolites 16α-hydroxyestrone (3,16α-Dihydroxy-1,3,5(10)-estratrien-17-one) (Steraloids Inc., New-port, USA) and 4-hydroxyestradiol (Estra-1,3,5(10)-triene-3,4,17ß-triol) (Sigma-Aldrich Corp., St. Louis, USA) were dissolved in 96% ethanol (P.P.H. POCh S.A.) to a concentration of 10 mM stock solution and used diluted in PBS for every experiment at concentrations of 1.0 µM, 5.0 µM and 10.0 µM.
Appropriate controls were assayed in parallel to the samples. All the experiments were performed gradually, using different sources of red blood cells and mitochondria in each exposure scenario.
Determination of TBARS concentration

In mitochondria
The mitochondrial suspension (1 mL) was incubated in a water bath with a shaker at 37°C for 30 min with 30 µL of CrVI, 16α-OHE 1 , 4-OHE 2 or a mixture (to assess interaction). The incubation was stopped by adding 0.5 mL of 20% trichloroacetic acid (TCA). Then 1.5 mL of 0.67% thiobarbituric acid (TBA) and 30 µL of 1% buthylhydroxytoluene (BHT) were added and the samples were heated at 95°C for 15 min. The cooled mixture was centrifuged to pellet the protein. The TBARS concentration was measured spectrophotometrically at 535 nm and expressed as nM per mg of mitochondrial protein, using the molar absorption coefficient 1.56 × 105 M -1 cm
The effects of metabolite interactions with chromium VI on TBARS concentration were examined in every concentration: 4-OHE 2 and 16α-OHE 1 at 1.0 µM, 5.0 µM and 10.0 µM; CrVI at 0.05 μg/mL, 0.5 μg/mL and 1.0 μg/mL. First the mitochondria were incubated at 37°C for 30 min with 16α-OH or 4-OHE 2 at the appropriate concentration, then chromium VI was added to the sample and the incubation was continued at 37°C for 30 min. Then the TBARS concentration was measured by the method described above.
In erythrocytes
The compounds being studied were added in 20 µL quantities to 2 mL of erythrocyte suspension prepared as described above, and the samples were incubated at 37°C for 0.5 h in a water bath with shaker. The TBARS concentration was then measured as described by Stocks et al. 13 The concentration of lipid peroxidation products was read from a standard curve, prepared with tetra ethoxypropane and expressed in nM/g Hb. Hemoglobin in the blood was determined using Drabkin's reagent.
Determination of hydroxyl radical generation
The mitochondrial suspension (0.5 mL) was incubated at 37°C (15 min) with 15 µL of 1% t-BOOH, 0.5 mL of 20 mM deoxyribose and either 4-OHE 2 , 16α-OHE 1 or CrVI; and to assess interactions, 4-OHE 2 combined with CrVI, or 16α-OHE 1 combined with CrVI. After incubation, the samples were centrifuged and 0.8 mL of the supernatant was collected; then 0.5 mL of 2.8% TCA and 0.5 mL of 1% TBA in 0.1 M NaOH were added to the supernatant. The samples were incubated at 100°C for 20 min, then cooled and centrifuged. The level of •OH generation was measured spectrophotometrically at 532 nm and calculated using the molar coefficient of absorption 1 
Determination of superoxide dismutase activity
Superoxide dismutase activity was measured with a RANSOD kit (Randox Laboratories Ltd., Crumlin, UK) according to the manufacturer's instructions. 15, 16 The assay is based on the xanthine oxidase reaction, where superoxide anion product reacts with 2−(4−iodophenyl)−3−(4−nitro−phenol)−5−phenyltetrazolium chloride (INT) to form a red formazan dye measured at a wavelength of 492 nm. The strength of inhibition of formazan dye formation reflects the activity of SOD in the tested sample. The assay mixture, with a final volume of 0.2 mL, included xanthine oxidase, xanthine, INT and the sample. Absorbance was measured at 492 nm after the addition of xanthine oxidase. On the basis of the absorbance increase after 1 min and comparison with the calibration curve, the percentage of reaction inhibition and hence of SOD activity was calculated according to the kit manufacturer's instructions. The results were compared with a sample containing CrVI, prepared in the same way, but without estrogens.
Determination of glutathione-S-transferase activity
Glutathione S-transferase activity was assayed using 1-Chloro-2, 4-dinitrobenzene (CDNB), which is suitable for the broadest range of GST isoenzymes. 17 Upon conjugation of the thiol group of glutathione to the CDNB substrate, there is an increase in absorbance at 340 nm. Solutions of samples containing CrVI, 16α-OHE 1 , 4-OHE 2 or mixtures of them were mixed with the substrate on a shaker, and the absorbance was immediately measured at a wavelength of λ = 340 nm on a plate reader (StatFax 2100 Awareness Technology, Block Scientific Inc., Bellport, USA). The increase in absorbance in the tested sample was directly proportional to the GST activity.
In order to evaluate the effect of estradiol metabolites on human placental mitochondria or erythrocytes stimulated with CrVI, the mitochondrial or erythrocyte suspension was preincubated at 37°C for 30 min with appropriate concentrations of the estradiol metabolites (16α-OHE 1 or 4-OHE 2 ). Then a solution of CrVI was added to the sample and incubation was continued at 37°C for 30 min. Finally, the level of the factor being tested was measured and compared with controls containing chromium in the appropriate concentration but without estradiol metabolites.
Statistical analyses
All statistical analyses were performed using Student's t-test or one-way ANOVA for repeated measurements. Differences between the groups were considered significant at p < 0.05. The variability of the distribution was checked with the Lilliefors test. Pearson's correlation coefficient was used to describe correlations. The statistical evaluation of the results was carried out using STATIS-TICA 10 software (StatSoft Inc., Tulsa, USA).
Results
The effect of CrVI compounds, 4-OHE 2 and 16-αOHE 1 on TBARS and •OH concentration, and on the activities of SOD and GST, both in mitochondria from human placenta and in erythrocytes from blood is presented. In order to better interpret the combined action of CrVI and the metabolites, the effect of the individual compounds (CrVI, 4-OHE 2 or 16-αOHE 1 ) on selected parameters in the mitochondria and erythrocytes was also presented (Table 1) .
It was found that all the concentrations of chromium VI used in the tests (0.05, 0.5 and 1.0 µg/mL) increased the lipid peroxidation measured by TBARS concentration in the mitochondrial and erythrocyte suspension in comparison with equivalent controls (Table 1 ). The combined action of estrogens and CrVI showed that 4-OHE 2 at a concentration of 1.00 µM significantly (p < 0.05) reduced the level of chromium-induced (0.05 and 0.5 µg/mL of CrVI) lipid peroxidation in erythrocytes. Decreases in TBARS concentrations were not observed for the highest chromium concentrations (Table 2) .
Unexpectedly, in mitochondria treated with CrVI, the metabolite 4-OHE 2 also reduced the TBARS level (p < 0.05) with a clear negative statistically significant dose/response dependency (Pearson correlation coefficient r = -0.972 for 0.05 µg/mL CrVI; r = -0.9494 for 0.5 µg/mL CrVI; r = -0.9856 for 1.0 µg/mL CrVI; p < 0.001) (Fig. 1) . The statistically significant effect of 4-OHE 2 was observed on lipid peroxidation caused by CrVI at all 3 doses: 0.05 μg/mL, 0.5 μg/mL and 1.0 μg/mL. The largest decrease in TBARS levels was at the highest concentration of 4-OHE 2 (10.0 µM). This is interesting, because the authors' previous report described17-β-estradiol (E 2 ) having the opposite effect on erythrocytes than on mitochondria exposed to chromium. 3 The other estradiol metabolite, 16α-OHE 1 , in contrast to 4-OHE 2 , did not decrease chromium-induced lipid peroxidation in erythrocytes and mitochondria (data not shown). It could therefore be concluded that 16α-OHE 1 did not participate in the decrease in lipid peroxidation shown by E 2 exposed to CrVI in the authors' previous study. 3 It appears that the positive effect of E 2 could be increased by its biotransformation to 4-OHE 2 , not to 16α-OHE 1 .
The studies of the joint effects of 4-OHE 2 or 16-αOHE 1 and CrVI in mitochondria revealed that neither of the metabolites in combination with CrVI influenced •OH generation (data not shown). These results suggest that the effect of the examined compounds on free radical processes engages a mechanism that is not dependent on the •OH level.
As to the enzyme activity studies, CrVI in doses of 0.05 µg/mL and 0.5 µg/mL decreases SOD in a statistically significant way in comparison to equivalent controls, in both erythrocytes and in mitochondria (p < 0.05) ( Table 1 ). The joint influence of metabolites and CrVI on SOD revealed the clear stimulative effects of all concentrations of 4-OHE 2 on SOD activity in erythrocytes exposed to CrVI; dose/response dependency was observed for CrVI in concentrations of 1.0 µg/mL and 0.5 µg/mL (r = 0.5908 and r = 0.6041 respectively; p < 0.05).
Most of the data showed a statistically significant increase in SOD activity treated with 4-OHE 2 and CrVI in comparison to controls where erythrocytes were exposed to chromium alone (Fig. 2) . As in erythrocytes, 4-OHE 2, significantly increased SOD activity in mitochondria exposed to CrVI (Table 3) , but without clear dose/response dependency. No effects of 16α-OHE 1 on SOD activity in erythrocytes or mitochondria were observed (data not shown).
In all the doses used, chromium VI decreased GST activity in erythrocytes and in mitochondria (p < 0.05) in comparison to equivalent controls (0) ( Table 1 ). In erythrocytes exposed to 0.05 μg/mL, 0.5 μg/mL and 1.0 μg/mL of CrVI, the metabolite 16α-OHE 1 caused a clear increase in GST activity (Fig. 3) . The most significant effect was observed when erythrocytes were exposed to the lowest dose of CrVI (0.05 μg/mL). The effect on mitochondria was not significant (data not shown). No influence of 4-OHE 2 on GST activity was observed in erythrocytes or mitochondria exposed to CrVI.
To summarize, it was observed that neither 4-OHE 2 and 16α-OHE has toxic reactions to CrVI; on the contrary, they even show positive, protective effects in mitochondria and in erythrocytes exposed to CrVI: 4-OHE 2 decreases lipid peroxidation in mitochondria and erythrocytes, increasing SOD activity. The positive role of 16α-OHE 1 involves a different mechanism, influencing phase-II detoxification by stimulating glutathione transferase activity.
Discussion
The role of estradiol in oxidative stress is prominent because it demonstrates free radical scavenging activities. This activity is enabled by the presence of a hydroxyl phenolic group that acts as a proton donor in chemical reactions. 18 The estrogenic radical formed in this deprotonation is stabilized by electron delocalization inside the aromatic ring. On the basis of this mechanism, it can be concluded that the estradiol metabolites 4-OHE 2 and 16α-OHE 1 should demonstrate similar properties, since both these compounds contain an aromatic ring substituted with a hydroxyl group. It follows that 4-OHE 2 should be an even stronger free-radical scavenger in cells than in the substrate, since it contains a second additional phenolic group typical of catecholestrogens. The catecholic structure favors transformation to o-quinone and semiquinone radicals, which are less toxic than the hydroxyl radical. The catecholic structure also has the ability to neutralize other free radicals. The quinons are reduced with quinine reductase or CYP reductase and removed by conjugation with reduced glutathione. 4 Some authors have demonstrated that 4-OHE 2 reduces the toxic effects of oxidative stress in cells and oxidative DNA-damage. [19] [20] [21] The current study also confirm the ability of 4-OHE 2 to decrease chromium VI-induced lipid peroxidation. The metabolism of estradiol is based mainly on hydroxylation reactions induced or blocked by endo-or exogenous compounds that induce or inhibit cytochrome P450. C-4 hydroxylation leads to 4-OHE 2 formation, but C-16 hydroxylation leads to 16α-OHE 1 .
The influence of estradiol and its metabolites on oxidative stress has been widely discussed in the literature, however there is little information about the role of estradiol in xenobiotic-induced oxidative stress. 22 Sowers et al. hypothesized that physiological levels of estradiol and its metabolites 2-hydroxyestrone and 16α-hydroxyestrone decrease oxidative stress measured as isoprostane levels in women's plasma; unfortunately, a test on 1647 smoking and non-smoking women at the age of 47-57 did not confirm this hypothesis. 23 On the other hand, Tang et al. showed that 4-hydroxyestrone acted as an inhibitor of lipid peroxidation in tissue cultures, while Seeger et al. demonstrated that 2-metoxyestrone and 2-hydroxyestrone blocked lipid peroxidation more efficiently than estradiol and 16α-hydroxyestrone in the serum of healthy subjects. 24, 25 Estrogens may act as pro-oxidants or antioxidants depend on their concentration. 26 The present study shows that in contrast to 4-OHE 2 , 16α-OHE 1 does not decrease CrVI-induced lipid peroxidation. The advantageous effect of 4-OHE 2 on lipid peroxidation in mitochondria suggests that the increase in TBARS in mitochondria exposed to chromium treated with 17β-estradiol described in the authors' earlier publication is in fact a result of substrate not metabolite interaction between E2 and CrVI; 4-OHE 2 is not involved in this interaction. 3 The mechanism of the antioxidative action of 4-OHE 2 in exposure to CrVI seems to be connected with stimulation of SOD activity, especially in erythrocytes exposed to CrVI. While previous studies have shown that CrVI compounds strongly inhibit SOD activity, the present work demonstrates that this effect can be repaired by 4-OHE 2 . 27 It can be concluded that increased formation of 4-OHE 2 in estradiol biotransformation appears beneficial for the inhibition of oxidative stress in mitochondria and erythrocytes exposed to CrVI compounds.
Human erythrocytes seem to be anappropriate model to study the estrogen-chromium effect on the antioxidative barrier. They contain antioxidative enzymes (SOD, catalase, GPx) and non-enzymatic antioxidants (vitamins C and E, beta-carotene and uric acid). Additionally, CrVI has the ability to accumulate in human erythrocytes. It has been shown that increased levels of estrogens in erythrocytes in female rats protect them from induced trauma/hemorrhagic shock (T/HS). In comparison to erythrocytes in male rats, a positive action in lowering red blood cells' deformability was observed. 28, 29 The current study compared 2 cell models. Both mitochondria and erythrocytes were sensitive to the influence of chromium-and estrogen-caused oxidative disturbances. In most cell types mitochondria are the predominant source of reactive oxygen species (ROS), including superoxide anion, H 2 O 2 and •OH. Although estrogen synthesis occurs in mitochondria, exogenously added estrogens are also transported to this organelle;their lipophilic properties allow them to diffuse through the lipid bilayer of cell membranes. 30 Mitochondria have a unique characteristic that allows them to participate in growth signal transduction. They are a regulatable source of ROS in response to external stimuli, for example metaloestrogens or estrogens. 31 Mitochondria are a major target of estrogens. It appears that through their interaction with the cytoskeleton, export of cleaved signaling peptides, and/or generation of ROS, mitochondria may transduce signals to the nucleus for the activation of transcription factors involved in the cell cycle progression of estrogen-dependent cells. These interactions between estrogens and mitochondria merit future investigation, which could shed new light on the role of mitochondria in cell growth. In the present study these organelles were used to examine the interactions between estrogens and metalloestrogen in reaction to oxidative stress. 25, 30, 32 Considering the results obtained in relation to CrVIinduced carcinogenesis, the 4-OHE 2 metabolite demonstrated a positive effect on the free radical reaction, while 16α-OHE 1 did not. These results support the general assumption that the introduction of another phenol group to the aromatic ring of estradiol (4-OHE2) increases the free radical scavenging properties of the metaboliteformed. The 16α-OHE 1 metabolite also shows a positive effect, but by a different mechanism. It influences the second phase of detoxification, thus increasing GST activity. It can be postulated that the biotransformation of estradiol to 4-OHE 2 and 16α-OHE 1 in exposure to CrVI has advantageous results.
Conclusions 4-hydroxyestradiol reduces the level of lipid peroxidation induced by CrVI compounds in mitochondria and in erythrocytes, increasing SOD activity. 16α-hydroxyestrone increases the activity of GST in erythrocytes exposed to CrVI.
